Clinical Trials
Phase 2 randomized, double-blind, placebo-controlled trials evaluated CKD 4/6 inhibitor administered prior to chemotherapy in patients with extensive-stage small cell lung cancer. Additional analysis was performed with these data.
This section includes links to Pharmacosmos sponsored-publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
Note: Trilaciclib was developed by G1 Therapeutics which is now a subsidiary of Pharmacosmos Therapeutics Inc
Trilaciclib
October 2021 I Int J Cancer
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
Gómez MD, Csőszi T, Jaal J , et al.
September 2021 I Cancer Med
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Ferrarotto R, Anderson I, Medgyasszay B, et al.
September 2021 I Clin Lung Cancer
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
Weiss J, Goldschmidt J, Andric Z, et al.
August 2021 I Cancer Manag Res
Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: Pooled results from three phase 2, randomized, double-blind, placebo-controlled studies
Hussein M, Maglakelidze M, Richards DA, et al.
May 2021 I Int J Cancer
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Daniel D, Kuchava V, Bondarenko I, , et al.
January 2021 I Adv Ther
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Stud
Hart LL, Ferrarotto R, Andric ZG, et al.
October 16-17, 2020 | IASLC North America Conference on Lung Cancer (Poster)
Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age
Beck JT, Richards DA, Agajanian R, et al.
October 16-17, 2020 | IASLC North America Conference on Lung Cancer (Poster)
Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer
Subramanian J, Jaal J, Kudaba I, et al.
October 2019 I Ann Oncol
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
Weiss JM, Csoszi T, Maglakelidze M, et al.